Immunogenicity of Quadrivalent Influenza Vaccine for Patients with Inflammatory Bowel Disease Undergoing Immunosuppressive Therapy

Autor: Yasuyuki Gomi, Ryuichi Iwakiri, Koji Yamamoto, Megumi Hara, Shimpei Shirai, Ryo Shimoda, Hironori Yoshii, Yasuhisa Sakata, Nanae Tsuruoka, Kazuma Fujimoto
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Quadrivalent Inactivated Influenza Vaccine
Crohn’s disease
Adult
Male
medicine.medical_specialty
medicine.disease_cause
Inflammatory bowel disease
03 medical and health sciences
0302 clinical medicine
Immunogenicity
Vaccine
Influenza A Virus
H1N1 Subtype
Japan
Internal medicine
Influenza
Human
medicine
Influenza A virus
Immunology and Allergy
Humans
030212 general & internal medicine
Prospective Studies
Seroconversion
ulcerative colitis
Crohn's disease
Original Research Articles–Clinical
business.industry
Tumor Necrosis Factor-alpha
Immunogenicity
Influenza A Virus
H3N2 Subtype
Vaccination
Gastroenterology
Hemagglutination Inhibition Tests
medicine.disease
Inflammatory Bowel Diseases
Infliximab
Influenza B virus
Influenza Vaccines
030211 gastroenterology & hepatology
Female
business
Immunosuppressive Agents
medicine.drug
Zdroj: Inflammatory Bowel Diseases
ISSN: 1536-4844
1078-0998
Popis: Background and Aims No reports have described the immunogenicity and boosting effect of the quadrivalent inactivated influenza vaccine (QIV) in adults with inflammatory bowel disease. Methods Adults with Crohn’s disease or ulcerative colitis were randomly assigned to a single vaccination group or booster group, and a QIV was administered subcutaneously. Serum samples were collected before vaccination, 4 weeks after vaccination, and after the influenza season in the single vaccination group. In the booster group, serum samples were taken before vaccination, 4 weeks after the first vaccination, 4 weeks after the second vaccination, and after the influenza season. We measured hemagglutination inhibition antibody (HAI) titer and calculated the geometric mean titer ratio (GMTR), seroprotection rate, and seroconversion rate. Results In total, 132 patients were enrolled. Twenty-two patients received immunomodulatory monotherapy and 16 received anti-tumor necrosis factor-α (anti-TNF-α) single-agent therapy. Fifteen patients received combination therapy comprising an immunosuppressant and anti-TNF-α agent. Each vaccine strain showed immunogenicity satisfying the European Medicines Agency criteria with a single inoculation. The booster influenza vaccination did not induce additional response. In patients administered infliximab, the seroprotection rate and seroconversion rate tended to be lower in patients who maintained blood concentrations [seroprotection rate: H1N1: OR, 0.37 (95% CI, 0.11–1.21); H3N2: 0.22 (0.07–0.68); seroconversion rate: H1N1: 0.23 (0.06–0.91); H3N2: 0.19 (0.06–0.56)]. Conclusion Single dose QIV showed sufficient immunogenicity in patients with inflammatory bowel disease, and a boost in immunization by additional vaccination was not obtained. Additionally, immunogenicity was low in patients receiving infliximab therapy.
Databáze: OpenAIRE
Externí odkaz: